These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Problems in the development of immunoglobulin preparations]. Friedli H Beitr Infusionsther; 1989; 24():95-101. PubMed ID: 2481555 [TBL] [Abstract][Full Text] [Related]
23. [Therapeutic use of human immunoglobulin]. Ljaljević J; Bogić M; Tomasević Lj; Nedok O; Rasković S; Petković B; Stefanović Lj; Dimcić Z Glas Srp Akad Nauka Med; 1994; (44):133-7. PubMed ID: 7590411 [TBL] [Abstract][Full Text] [Related]
24. [Current developments in the use of intravenous immunoglobulins]. Bardare M; Dellepiane RM Minerva Pediatr; 1991 Nov; 43(11):665-74. PubMed ID: 1791793 [TBL] [Abstract][Full Text] [Related]
25. Requirements for safety and quality of intravenous immunoglobulin G preparations. Rütter GH J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):2-5. PubMed ID: 7964845 [TBL] [Abstract][Full Text] [Related]
26. Research and development commitments in an integrated plasma collection and plasma fractionation environment. Radosevich M Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637 [TBL] [Abstract][Full Text] [Related]
27. [Plasma fractionation in the world: current status]. Burnouf T Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539 [TBL] [Abstract][Full Text] [Related]
28. A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process. Teschner W; Butterweck HA; Auer W; Muchitsch EM; Weber A; Liu SL; Wah PS; Schwarz HP Vox Sang; 2007 Jan; 92(1):42-55. PubMed ID: 17181590 [TBL] [Abstract][Full Text] [Related]
29. Differences between IGIV products: impact on clinical outcome. Gelfand EW Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921 [TBL] [Abstract][Full Text] [Related]
31. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Prins C; Gelfand EW; French LE Acta Derm Venereol; 2007; 87(3):206-18. PubMed ID: 17533485 [TBL] [Abstract][Full Text] [Related]
32. Effects of intravenous immunoglobulins on T cell and oligodendrocyte apoptosis in high-dose antigen therapy in experimental autoimmune encephalomyelitis. Weishaupt A; Kuhlmann T; Schönrock LM; Toyka KV; Brück W; Gold R Acta Neuropathol; 2002 Oct; 104(4):385-90. PubMed ID: 12200625 [TBL] [Abstract][Full Text] [Related]
33. Successful management of neutropenia in a patient with CD40 ligand deficiency by immunoglobulin replacement therapy. Atarod L; Aghamohammadi A; Moin M; Kanegane H; Rezaei N; Rezaei Kalantari K; Amirzagar AA; Futatani T; Miyawaki M Iran J Allergy Asthma Immunol; 2007 Mar; 6(1):37-40. PubMed ID: 17303928 [TBL] [Abstract][Full Text] [Related]
34. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545 [TBL] [Abstract][Full Text] [Related]
35. Flebogamma(®) DIF (intravenous immunoglobulin) purification process effectively eliminates procoagulant activities. José M; Marzo N; Pons B; Herrerias A; López L; Faro M; López M; Jorquera JI Biologicals; 2013 Nov; 41(6):393-9. PubMed ID: 24051302 [TBL] [Abstract][Full Text] [Related]
36. Clinical experience with polyclonal IgM-enriched immunoglobulins in a group of patients affected by sepsis after cardiac surgery. Buda S; Riefolo A; Biscione R; Goretti E; Cattabriga I; Grillone G; Bacchi-Reggiani L; Pacini D J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):440-5. PubMed ID: 16085247 [TBL] [Abstract][Full Text] [Related]